Isoforms of KMTs | Target residues | Kinases | Functional regulation upon phosphorylation | Involved in diseases and signaling pathways | References |
---|---|---|---|---|---|
HDAC1 | Thr65 | CaMKII | Activation of enzymatic activity | Heart failure | [163] |
Ser69 | |||||
Ser85 | |||||
Thr195 | |||||
Ser197 | |||||
Thr355 | |||||
Tyr72 | EGFR | Stabilization | Cancer cell survival | [134] | |
Ser406 | Aurora A/B | Activation of enzymatic activity | Zebrafish embryos development | [133] | |
Ser423 | CK2 | Enhance of its interaction with SIN3A | Cell cycle | [164] | |
Ser421 | CK2 | ||||
NLK | Disruption of its interaction with LEF1 | WNT signaling pathway | [131] | ||
HDAC2 | Ser407 | CK2 | Disruption of its interaction with RARα | Proliferation of vascular smooth muscle cells | [137] |
Ser394 | CK2 | Inhibition of enzymatic activity | Inflammation | [136] | |
Ser422 | |||||
Ser424 | |||||
HDAC3 | Ser374 | CaMKII | Inhibition of enzymatic activity | Heart failure | |
HIPK2 | Inhibition of enzymatic activity | Colorectal carcinoma and sepsis | [144] | ||
Ser424 | CK2 | Activation of enzymatic activity | Tumorigenesis | [139] | |
TBK1 | Activation of enzymatic activity | Innate antiviral immunity | [140] | ||
LRRK2 | Activation of enzymatic activity | Parkinson’s disease | [140] | ||
c-Jun N-terminal kinase | Activation of enzymatic activity | Triple-negative breast cancer | [142] | ||
PINK1 | Activation of enzymatic activity | Parkinson’s disease | [143] | ||
HDAC4 | Ser246 | TBK1/IKKε | Suppression of IRF3 phosphorylation | Innate immune | [165] |
CaMKIV | Enhance of its interaction with 14-3-3 | DNA binding | [166] | ||
PKD | Nuclear extrusion into the cytoplasm | Mitogenic signaling | [167] | ||
CaMKII | Disruption of its interaction with MEF2 | Skeletal muscle hypertrophy | [148] | ||
Ser467 | CaMKIV | Enhance of its interaction with 14-3-3 | DNA binding | [166] | |
CaMKII | Nuclear extrusion into the cytoplasm | Metabolism | [149] | ||
Ser632 | CaMKIV | Enhance of its interaction with 14-3-3 | DNA binding | [166] | |
PKD | Nuclear extrusion into the cytoplasm | Mitogenic signaling | [167] | ||
PP2A | Nuclear extrusion into the cytoplasm | Neurodegeneration | [168] | ||
Ser740 | PKA | Stabilization | Bone and chondrocyte development | [151] | |
HDAC5 | Ser259 | AMPK | Nuclear extrusion into the cytoplasm | WNT signaling pathway | [155] |
PKD | Enhance of its interaction with 14-3-3 | Cardiac myocyte hypertrophy | [153] | ||
AKT | Nuclear extrusion into the cytoplasm | Vascular disorders | [155] | ||
CaMKII | Nuclear extrusion into the cytoplasm | Diabetes | [156] | ||
SIK1 | Chromatin remodeling | Cardiac hypertrophy | [169] | ||
PKCδ | Nuclear extrusion into the cytoplasm | Heart failure | [170] | ||
Ser280 | PKA | Disruption of its interaction with 14-3-3 | cAMP/PKA signaling pathway | [171] | |
Thr292 | PRK1 | Disruption of its interaction with 14-3-3 | Â | [172] | |
Ser493 | GRK5 | Nuclear extrusion into the cytoplasm | Heart failure; NF-κB signaling pathway | [173] | |
Ser498 | AMPK | Nuclear extrusion into the cytoplasm | WNT signaling pathway | [154] | |
PKD | Enhance of its interaction with 14-3-3 | Cardiac myocyte hypertrophy | [153] | ||
AKT | Nuclear extrusion into the cytoplasm | Vascular disorders- | [155] | ||
PKA | Nuclear extrusion into the cytoplasm | Heart failure | [174] | ||
Tyr642 | FAK | Nuclear extrusion into the cytoplasm | Osteocyte mechanotransduction | [174] | |
Ser661 | PKA | Nuclear extrusion into the cytoplasm | Heart failure | [170] | |
Ser611 | Unknown | Enhance of its interaction with other proteins | Cell cycle | [175] | |
Ser755 | |||||
Ser1108 | |||||
HDAC6 | Ser21 | GRK5 | Activation of enzymatic activity | Cancer | [158] |
Ser22 | GSK3β | Activation of enzymatic activity | Parkinson’s disease | [159] | |
Ser289 | ASK1 | Stabilization | Retinopathy of prematurity | [176] | |
Thr293 | |||||
Ser458 | CK2 | Activation of enzymatic activity | Aggregation of misfolded proteins | [160] | |
Tyr570 | EGFR | Inhibition of enzymatic activity | Receptor endocytosis and degradation | [162] | |
Ser1031 | ERK1 | Â | Cell migration | [161] | |
Ser1035 | ERK1 | Activation of enzymatic activity | |||
HDAC7 | Ser155 | PKD1 | Nuclear extrusion into the cytoplasm | Apoptosis | [177] |
Ser178 | PKD1 | Nuclear extrusion into the cytoplasm | Cell proliferation and migration; VEGF signaling pathway | [178] | |
CaMKI | Nuclear extrusion into the cytoplasm | Angiogenesis | [179] | ||
CRM1 | Nuclear extrusion into the cytoplasm | Myogenesis | [180] | ||
Ser181 | PKD1 | Nuclear extrusion into the cytoplasm | Bone formation and maintenance | [181] | |
Ser318 | PKD1 | Nuclear extrusion into the cytoplasm | Apoptosis | [180] | |
Ser344 | PKD1 | Nuclear extrusion into the cytoplasm | Cell proliferation and migration; VEGF signaling pathway | [177] | |
CaMK I | Nuclear extrusion into the cytoplasm | Angiogenesis | [178] | ||
Ser448 | PKD1 | Nuclear extrusion into the cytoplasm | Apoptosis | [180] | |
Ser479 | PKD1 | Nuclear extrusion into the cytoplasm | Cell proliferation and migration; VEGF signaling pathway | [181] | |
CaMKI | Nuclear extrusion into the cytoplasm | Angiogenesis | [177] | ||
HDAC8 | Ser39 | AMPK | Nuclear extrusion into the cytoplasm | Lung cancer cell survival | [147] |
PKA | Inhibition of enzymatic activity | Â | [182] | ||
Ser43 | AMPK | Nuclear extrusion into the cytoplasm | Lung cancer cell survival | [147] | |
Ser63 | AMPK | ||||
HDAC9 | Ser218 | PKD | Disruption of its interaction with 14-3-3 | Cardiac hypertrophy | [152] |
Ser448 |